Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer
Launched by JICHAO QIN · Dec 8, 2024
Trial Information
Current as of June 16, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how cancer spreads to lymph nodes in the short gastric mesentery, which is part of the stomach area, after a total gastrectomy (a surgery to remove the stomach) combined with a specific type of lymph node removal. The goal is to gather important information that could help doctors standardize how they perform lymph node dissection in patients with gastric cancer, aiming to improve treatment outcomes.
To be eligible for this trial, participants need to be between 18 and 85 years old and have a confirmed diagnosis of gastric adenocarcinoma, a type of stomach cancer. They should not have advanced cancer that has spread to other parts of the body, and they must have undergone the specific surgery mentioned. Participants will need to provide written consent to join the study. As the trial is not yet recruiting, those interested will need to wait for further announcements about when it will begin. This research could be crucial in shaping future cancer treatment approaches.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged older than 18 years and younger than 85 years
- • 2. Primary gastric adenocarcinoma confirmed by preoperative pathology result
- • 3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
- • 4. Patients who received total gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
- • 5. American Society of Anesthesiologists (ASA) class I, II, or III
- • 6. Written informed consent
- Exclusion Criteria:
- • 1. Negative preoperative biopsy
- • 2. Too late tumour stage or metastasis (cT4b/M1)
- • 3. BMI\>30 kg/m2
- • 4. previous neoadjuvant chemotherapy or radiotherapy
- • 5. Previous upper abdominal surgery
- • 6. Combined with other malignant diseases
- • 7. Reject operation
About Jichao Qin
Jichao Qin is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With expertise in trial design and execution, Jichao Qin focuses on innovative therapeutic areas, ensuring rigorous adherence to regulatory standards and ethical considerations. The organization actively collaborates with healthcare professionals and research institutions to facilitate the development of new treatments, fostering a culture of transparency and scientific integrity. Through a patient-centered approach, Jichao Qin aims to contribute significantly to the advancement of evidence-based medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported